Coastal Infusion Administers Skyrizi®

Skyrizi (risankizumab) is used to treat moderate-to-severe plaque psoriasis, and psoriatic arthritis, when traditional disease-modifying anti-rheumatic drugs (DMARDs) have proven ineffective or have led to intolerable side effects. Skyrizi has also been approved to treat moderate-to-severe Crohn’s Disease, when conventional or biological treatments have not yielded satisfactory results or have caused unacceptable side effects.

The active substance in Skyrizi, risankizumab, is a monoclonal antibody that is designed to attach to interleukin-23 (IL-23) and block its activity. By blocking the action of IL-23, risankizumab reduces inflammation and other symptoms associated with these conditions.

What It Treats

• Crohn’s Disease
• Plaque Psoriasis
• Psoriatic Arthritis

Prescribed By

Skyrizi is most often prescribed by Dermatologists and Rheumatologists.

How it’s Administered

Skyrizi is administered by subcutaneous injection. Skyrizi injections take only a few minutes.

Frequency

Skyrizi is generally administered every 12 weeks after two starter doses, four weeks apart.

Related Drugs

Bimzelx, Cosentyx, Skyrizi, Tremfya

Additional Resources

• Skyrizi Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies